Cargando…
Duration of anti-SARS-CoV-2 antibodies much shorter in India
Seroprevalence survey, for antibodies to SARS-CoV-2, of healthcare workers (HCW) working in three Government run hospitals in Mumbai was carried out in June 2020. Among the 801 HCWs tested, seroprevalence was 11.1%. Males (13.5% vs. 8.9% in females) and ancillary workers (18.5% vs 6.9% in doctors an...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641879/ https://www.ncbi.nlm.nih.gov/pubmed/33189428 http://dx.doi.org/10.1016/j.vaccine.2020.10.094 |
_version_ | 1783606015318556672 |
---|---|
author | Kumar, Nishant Bhartiya, Shibal Singh, Tarundeep |
author_facet | Kumar, Nishant Bhartiya, Shibal Singh, Tarundeep |
author_sort | Kumar, Nishant |
collection | PubMed |
description | Seroprevalence survey, for antibodies to SARS-CoV-2, of healthcare workers (HCW) working in three Government run hospitals in Mumbai was carried out in June 2020. Among the 801 HCWs tested, seroprevalence was 11.1%. Males (13.5% vs. 8.9% in females) and ancillary workers (18.5% vs 6.9% in doctors and nurses) were more likely to be seropositive. Sixty-two (7.74%) had been previously diagnosed with RT PCR test for SARS-CoV-2. Of these, 44 (71%) were seronegative. Upto 28 days after a positive PCR test, 90% of subjects were found to be seropositive. This reduced to less than half (38.5%) between 29 and 42 days. None of 28 infected HCWs who had the RT-PCR more than 50 days ago tested positive for antibodies. It seems likely that cellular immunity plays a larger role in defence against the illness. |
format | Online Article Text |
id | pubmed-7641879 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76418792020-11-05 Duration of anti-SARS-CoV-2 antibodies much shorter in India Kumar, Nishant Bhartiya, Shibal Singh, Tarundeep Vaccine Short Communication Seroprevalence survey, for antibodies to SARS-CoV-2, of healthcare workers (HCW) working in three Government run hospitals in Mumbai was carried out in June 2020. Among the 801 HCWs tested, seroprevalence was 11.1%. Males (13.5% vs. 8.9% in females) and ancillary workers (18.5% vs 6.9% in doctors and nurses) were more likely to be seropositive. Sixty-two (7.74%) had been previously diagnosed with RT PCR test for SARS-CoV-2. Of these, 44 (71%) were seronegative. Upto 28 days after a positive PCR test, 90% of subjects were found to be seropositive. This reduced to less than half (38.5%) between 29 and 42 days. None of 28 infected HCWs who had the RT-PCR more than 50 days ago tested positive for antibodies. It seems likely that cellular immunity plays a larger role in defence against the illness. Elsevier Ltd. 2021-02-05 2020-11-04 /pmc/articles/PMC7641879/ /pubmed/33189428 http://dx.doi.org/10.1016/j.vaccine.2020.10.094 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Kumar, Nishant Bhartiya, Shibal Singh, Tarundeep Duration of anti-SARS-CoV-2 antibodies much shorter in India |
title | Duration of anti-SARS-CoV-2 antibodies much shorter in India |
title_full | Duration of anti-SARS-CoV-2 antibodies much shorter in India |
title_fullStr | Duration of anti-SARS-CoV-2 antibodies much shorter in India |
title_full_unstemmed | Duration of anti-SARS-CoV-2 antibodies much shorter in India |
title_short | Duration of anti-SARS-CoV-2 antibodies much shorter in India |
title_sort | duration of anti-sars-cov-2 antibodies much shorter in india |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641879/ https://www.ncbi.nlm.nih.gov/pubmed/33189428 http://dx.doi.org/10.1016/j.vaccine.2020.10.094 |
work_keys_str_mv | AT kumarnishant durationofantisarscov2antibodiesmuchshorterinindia AT bhartiyashibal durationofantisarscov2antibodiesmuchshorterinindia AT singhtarundeep durationofantisarscov2antibodiesmuchshorterinindia |